Cardiovascular risk in the spectrum of type 2 diabetes mellitus

Mount Sinai Journal of Medicine

Volumn 73, Issue 5, 2006, Pages 759-768

  Ahmed, Intekhab ^a   Goldstein, Barry J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Insulin resistance; Metabolic syndrome; Metformin; Myocardial infarction; Obesity; Sulfonylureas; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG HYPERSENSITIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; REVIEW; RISK FACTOR; RISK REDUCTION; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; RISK ASSESSMENT; RISK FACTORS;

EID: 33749030680     PISSN: 00272507     EISSN: 00272507     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289-2304.
2. Harris MI. Diabetes in America: epidemiology and scope of the problem. Diabetes Care 1998; 21 Suppl 3:C11-C14.
3. DCCT Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14):977-986.
4. Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
5. Brand FN, Kannel WB, Evans J, et al. Glucose intolerance, physical signs of peripheral artery disease, and risk of cardiovascular events: the Framingham Study. Am Heart J 1998; 136(5):919-927.
6. Eckel RH. Perspectives on vascular biology and diabetes. J Invest Med 2001; 49:100-103.
7. Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med 2003; 115 Suppl 8A:6S-11S.
8. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348:2294-2303.
9. Gerstein HC. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor. Ann Intern Med 2004; 141:475-476.
10. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412.
11. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective, investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322:15-18.
12. Balkau B, Hu G, Qiao Q, et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004; 47:2118-2128.
13. Reaven GM. Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab 2005; 1(1):9-14.
14. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002; 90:3-10.
15. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15(3):318-368.
16. Carey DG, Jenkins AB, Campbell LV, et al. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45:633-638.
17. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365:1333-1346.
18. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106:171-176.
19. Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 121-124.
20. Rajala MW, Scherer PE. Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Clin Exp Pharmacol Physiol 2003; 144: 3765-3773.
21. Lazar MA. How obesity causes diabetes: not a tall tale. Science 2005; 307:373-375.
22. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45:828-833.
23. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/ NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003; 27 Suppl. 3:S49 -S52.
24. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307:384-387.
25. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004; 89:2563-2568.
26. Trujillo ME, Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257:167-175.
27. Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54:534-539.
28. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1(1): 15-25.
29. Fryer LG, Carling D. AMP-activated protein kinase and the metabolic syndrome. Biochem Soc Trans 2005; 33(Pt 2):362-366.
30. Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 1992; 41:1076-1083.
31. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Clin Exp Pharmacol Physiol 2003; 144:2195-2200.
32. Kuroki T, Isshiki K, King GL. Oxidative stress: the lead or supporting actor in the pathogenesis of diabetic complications. J Am Soc Nephrol 2003; 14:S216-S220.
33. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108:1527-1532.
34. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Reviews 1999; 7:139-153.
35. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137:25-33.
36. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005; 54:2460-2470.
37. Turner RC, Holman RR, Stratton IM, et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865.
38. Wulffele MG, Kooy A, Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004; 256:1-14.
39. De Jager J, Kooy A, Lehert PH, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005; 257(1):100-109.
40. Millican S, Cottrell N, Green B. Do risk factors for lactic acidosis influence dosing of metformin? J Clin Pharm Ther 2004; 29:449-454.
41. Lebovitz HE. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol 2002; 90:34G-41G.
42. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164:2097-2104.
43. Bakris G. Proteinuria: a link to understanding changes in vascular compliance? Hypertension 2005; 46:473-474.
44. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17(1):5-6.
45. Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679-684.
46. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51(9):2796-2803.
47. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004; 27:1349-1357.
48. Dandona P, Aljada A. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. J Diabetes Complications 2004; 18(2):91-102.
49. St. John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25(11):2058-2064.
50. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281:2005-2012.
51. Rosenstock J, Goldstein BJ, Vinik AI, et al.; RESULT Study Group. Effect of early addition of rosiglitazone to sulfonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULfonylurea Titration (RESULT) study. Diabetes Obes Metab 2006; 8(1):49-50.
52. Bell DS, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 2002; 8(4):271-275.
53. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5):383-393.